Back to top

gene-therapy: Archive

Zacks Equity Research

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.

SRPTPositive Net Change RNANegative Net Change ARWRPositive Net Change PEPGNegative Net Change

Zacks Equity Research

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

RHHBYNegative Net Change ALKSNegative Net Change SRPTPositive Net Change CRMDNegative Net Change